BioMarin Pharmaceuticals BMRN Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's accounts payable?
- BioMarin Pharmaceuticals (BMRN) reported accounts payable of $793.15M in Q1 2026.
- How has BioMarin Pharmaceuticals's accounts payable changed year-over-year?
- BioMarin Pharmaceuticals's accounts payable increased by 26.3% year-over-year, from $628.21M to $793.15M.
- What is the long-term trend for BioMarin Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's accounts payable has grown at a 9.0% compound annual growth rate (CAGR), from $492.55M to $759.03M.
- What does accounts payable mean?
- Money the company owes to its suppliers for goods or services already received.
- How do you interpret accounts payable?
- An increase can signal improved cash management or delayed payments, while a decrease may suggest faster settlement of obligations.
- How does accounts payable compare across companies?
- Standard working capital metric; peers in the pharmaceutical industry typically maintain consistent payment cycles.